| Preview | Issue Date | Title / Name | Author(s) |
| Dec-2013 | Docetaxel and dasatinib or placebo in men with metastatic castration-resistant prostate cancer (READY): a randomised, double-blind phase 3 trial | Araujo, J. C.; Trudel, G. C.; Saad, F.; Armstrong, A. J.; Yu, E. Y.; Bellmunt, J.; Wilding, G.; McCaffrey, J.; Serrano, S. V.; Matveev, V. B.; Efstathiou, E.; Oudard, S.; Morris, M. J.; Goebell, P. J.; Heidenreich, A.; de Bono, J. S.; Begbie, S.; et. al; Begbie, Stephen | |
| Jul-2019 | Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer | Davis, I. D.; Martin, A. J.; Stockler, M. R.; Begbie, S.; Chi, K. N.; Chowdhury, S.; Coskinas, X.; Frydenbuerg, M.; Hague, W. E.; Horvath, L. G.; Joshua, A. M.; Lawrence, N. J.; Marx, G.; McCaffrey, J.; McDermott, R.; McJannett, M.; North, S. A.; Parnis, F.; Parulekar, W.; Pook, D. W.; Reaume, M. N.; Sandhu, S. K.; Tan, A.; Tan, T. H.; Thomson, A.; Tu, E.; Vera-Badillo, F.; Williams, S, G,; Yip, S.; Zhang, A. Y.; Zielinski, R. R.; Sweeney, C. J.; Begbie, Stephen | |
| Mar-2022 | Health-related quality of life in metastatic hormone-sensitive prostate cancer: ENZAMET (ANZUP 1304), an international randomized phase III trial led by ANZUP | Stockler, M. R.; Martin, A. J.; Davis, I. D.; Dhillon, H. M.; Begbie, S. D.; Chi, K. N.; Chowdhury, S.; Coskinas, X.; Frydenberg, M.; Hague, W. E.; Horvath, L. G.; Joshua, A. M.; Lawrence, N. J.; Marx, G. M.; McCaffrey, J.; McDermott, R.; McJannett, M.; North, S. A.; Parnis, F.; Parulekar, W. R.; Pook, D. W.; Reaume, M. N.; Sandhu, S.; Tan, A.; Tan, T. H.; Thomson, A.; Vera-Badillo, F.; Williams, S. G.; Winter, D. G.; Yip, S.; Zhang, A. Y.; Zielinski, R. R.; Sweeney, C. J.; ENSAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Begbie, Stephen | |
| Sep-2021 | Overall survival of men with metachronous metastatic hormone-sensitive prostate cancer treated with enzalutamide and androgen deprivation therapy | Sweeney, C. J.; Martin, A. J.; Stockler, M. R.; Begbie, S.; Chi, K. N.; Chowdhury, S.; Coskinas, X; Frydenberg, M.; Hague, W. E.; Horvath, L. G.; Joshua, A. M.; Lawrence, N. J.; Marx, G. M.; McCaffrey, J.; McDermott, R.; McJannett, M.; North, S. A.; Parnis, F.; Parulekar, W.; Pook, D. W.; Reaume, M. N.; Sandhu, S. K.; Tan, A.; Tan, T. H.; Thomson, A.; Tu, E.; Vera-Badillo, F.; Williams, S. G.; Yip, S.; Zhang, A. Y.; Zielinski, R. R.; Davis, I. D.; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP); Begbie, Stephen | |
| Feb-2026 | Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304) | Inderjeeth, A-J.; Martin, A.J.; Zielinski, R.R.; Begbie, S.; Cheung, L.; Chowdhury, S.; Frydenberg, M.; Horvath, L.G.; Joshua, A.M.; Lawrence, N.J.; Marx, G.; McCaffrey, J.; McDermott, R.S.; McJannett, M.; North, S.A.; Parnis, F.; Parulekar, W.R.; Pook, D.W.; Reaume, M.N.; Sandhu, S.; Tan, A.; Tan, T.H.; Thomson, A.H.; Vera-Badillo, F.; Williams, S.G.; Thomas, H.; Yip, S.; Zhang, A.Y.; Chi, K.N.; Stockler, M.R.; Sweeney, C.J.; Davis, I.D.; ENZAMET Trial Investigators and the Australian and New Zealand Urogenital and Prostate Cancer Trials Group.; Begbie, Stephen D. | |
| Apr-2023 | Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial | Sweeney, C. J.; Martin, A. J.; Stockler, M. R.; Begbie, S.; Cheung, L.; Chi, K. N.; Chowdhury, S.; Frydenberg, M.; Horvath, L. G.; Joshua, A. M.; Lawrence, N. J.; Marx, G.; McCaffrey, J.; McDermott, R.; McJannett, M.; North, S. A.; Parnis, F.; Parulekar, W.; Pook, D. W.; Reaume, M. N.; Sandhu, S. K.; Tan, A.; Tan, T. H.; Thomson, A.; Vera-Badillo, F.; Williams, S. G.; Winter, D.; Yip, S.; Zhang, A. Y.; Zielinski, R. R.; Davis, I. D.; ENZAMET trial investigators and Australian and New Zealand Urogenital and Prostate Cancer Trials Group; Begbie, Stephen | |
